ClinicalTrials.gg
CompletedNCT02013531Updated Mar 29, 2016Results posted

Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms

A Phase 3 interventional study of Brexpiprazole in Major Depressive Disorder and Anxiety, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 21 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-03-29.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
37
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 24 studies testing brexpiprazole in Depressive Disorder, Major — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Depressive Disorder, Major.

Enrollment
19th of 24
37 · median 189
Started
2013
with 6 others
Phase 3
16 of 24
none open now
Registered
13th of 24
by date
Lead sponsor
15 of 24
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 24 studies testing brexpiprazole in Depressive Disorder, Major, this one is the 19th largest by enrollment, is one of 7 that started in 2013, is one of 16 in phase 3, and was the 13th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 24 studies testing brexpiprazole in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About brexpiprazole

brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing brexpiprazole in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the efficacy and safety of flexibly dosed adjunctive brexpiprazole treatment in subjects with major depressive disorder and anxiety symptoms, who are experiencing an inadequate selective serotonin reuptake inhibitor (SSRI)/serotonin norepinephrine reuptake inhibitor (SNRI) response.

03

Conditions studied

  • Major Depressive Disorder
  • Anxiety

Keywords

  • schizophrenia
  • Major depressive disorder
  • Anxiety Symptoms
  • Mental Disorders
  • Psychotic Disorders
  • emotional withdrawal
  • antipsychotic
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Have a diagnosis of a single or recurrent, nonpsychotic episode of MDD as defined by the , Fourth Edition, Text Revision (DSM-IV-TR) and confirmed by both the Mini International Neuropsychiatric Interview (M.I.N.I.) and an adequate clinical psychiatric evaluation.
  • Have a treatment history of an inadequate ADT response to at least 1 ADT (but not > 3) for the current episode.
  • Have received a single, trial-approved, SSRI or SNRI at an adequate dose for

    ≥ 6 weeks prior to screening.

  • Are 18 to 65 years old at the time of consent (inclusive, and outpatients only).
  • Have a Hamilton Depression Rating Scale (HAM-D)-17-item Total Score ≥ 18 at screening and baseline.
  • Have a Hamilton Anxiety Rating Scale (HAM-A) Total Score ≥ 20 at screening and baseline.

Main Exclusion Criteria:

Subjects with any of the following current Axis I DSM-IV-TR diagnoses:

  • delirium
  • dementia
  • amnestic
  • other cognitive disorders
  • schizophrenia
  • schizoaffective disorder
  • other psychotic disorders
  • bipolar I disorder,
  • bipolar II disorder
  • bipolar disorder not otherwise specified (NOS)
  • eating disorders
  • anorexia nervosa
  • bulimia
  • obsessive compulsive disorder
  • post-traumatic stress disorder

Subjects with any of the following current Axis II DSM-IV-TR diagnoses:

  • borderline, antisocial
  • paranoid
  • schizoid
  • schizotypal
  • histrionic personality disorders
  • mental retardation.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    Brexpiprazole

    Up to 3 mg/day, once daily dose, tablets, orally

    Drug: Brexpiprazole

Interventions

  • Treatment (6 weeks) - Up to 3mg/day, once daily dose, tablets, orally

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

    The MADRS is utilized as the primary efficacy assessment of a participant's level of depression. The MADRS consists of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS Total Score is the sum of ratings for all 10 items. The possible Total scores are from 0 to 60, with higher values indicating worse outcome.

    Time frame: Baseline, Week 6

Secondary outcomes

  1. Mean Change in Clinical Global Impression-Severity (CGI-S) Total Score

    The severity of illness for each participant was rated using the CGI-S. To perform this assessment, the study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

    Time frame: Baseline, Week 6

  2. Mean Clinical Global Impression-Improvement (CGI-I) Score at Week 6.

    The improvement of each participants condition was rated for each participant using the CGI-I. The study physician rated the participants total improvement whether or not it was due entirely to drug treatment. To perform this assessment, the study physician answered the following question: "Compared to his/her condition at baseline, how much has the participant changed?" Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. The response at a given week was compared with the participants condition at Baseline prior to the first dose of study medication.

    Time frame: Baseline, Week 6

  3. Percentage of Participants With CGI-I Response Rate

    The improvement of each participants condition was rated for each participant using the CGI-I. The study physician rated the participants total improvement whether or not it was due entirely to drug treatment. To perform this assessment, the study physician answered the following question: "Compared to his/her condition at baseline, how much has the participant changed?" Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. The response at a given week was compared with the participants condition at Baseline prior to the first dose of study medication.

    Time frame: Week 1 to Week 6

  4. Percentage of Participants With a MADRS Response

    MADRS response rate, where response is defined as ≥ 50% reduction in respective total scores from Baseline to Week 6. The MADRS consists of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS Total Score is the sum of ratings for all 10 items. The possible Total scores are from 0 to 60, higher values indicate worse outcome.

    Time frame: Week 6

  5. Percentage of Participants With a MADRS Remission

    MADRS remission rate, where remission is defined as MADRS Total Score ≤ 10 and 50% reduction in MADRS Total Score from Baseline to Week 6. The MADRS consists of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS Total Score is the sum of ratings for all 10 items. The possible Total scores are from 0 to 60, higher values indicate worse outcome.

    Time frame: Week 6

  6. Mean Change From Baseline in Hamilton Depression Rating Scale (HAM-D17) Total Score

    The HAM-D17 was utilized as an assessment of a participants level of depression and was administered utilizing the Structured Interview Guide for the Hamilton Depression Rating Scale (SIGH-D). Detailed instructions for administration of this structured interview were provided in the SIGH-D. The HAM-D17 was administered at the following visits: screening, Baseline, and Week 6/ Early termination (ET). HAM-D17 is a 17-item questionnaire with a total score of 0 to 52 with higher scores indicating more depressive symptoms.

    Time frame: Baseline, Week 6

  7. Mean Change From Baseline in Hamilton Anxiety Rating Scale (HAM-A) Total Score

    The HAM-A was utilized for the evaluation of anxiety symptoms and was administered using the Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A). Detailed instructions for administration of this structured interview were provided in the SIGH-A. The HAM-A was administered at the following visits: screening, Baseline, Weeks 1, 2, 3, 4, and 6/ET. HAM-A is a 14-item scale with each item is scored on a scale from 0 (not present) to 4 (very severe) with a total score of 0 to 56, with higher scores indicating severe anxiety symptoms.

    Time frame: Baseline, Week 6

  8. Mean Change From Baseline in Sheehan Disability Scale (SDS) Mean Score

    The SDS was a self-rated instrument used to measure the effect of the participant's symptoms on work/school, social life, and family/home responsibilities. The SDS was a visual analogue scale that used spatio-visual, numeric, and verbal descriptive anchors simultaneously to assess disability across the 3 domains. The number most representative of how much each area was disrupted by symptoms was marked along the line from 0 = not at all to 10 = extremely. Scores of 5 and above were associated with significant functional impairment. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired).

    Time frame: Baseline, Week 6

  9. Mean Change From Baseline in Massachusetts General Hospital-Cognitive and Physical Functioning Questionnaire (MGH-CPFQ) Total Score

    The MGH-CPFQ was a participant-rated scale designed to assess cognitive and executive dysfunction including symptoms of fatigue in mood and anxiety disorders. The MGH-CPFQ consisted of 7 items, each rated on a scale from 1 (greater than normal functioning) to 6 (poorer than normal functioning). The total score of the 7 items ranged from 7 to 42, with higher scores indicative of a worse outcome. The MGH-CPFQ was administered at the following visits: Baseline and Week 6/ET.

    Time frame: Baseline, Week 6

  10. Mean Change From Baseline in Kellner Symptom Questionnaire (KSQ)

    KSQ is a subject-rated scale designed to assess distress using symptoms of depression, anxiety, anger-hostility and somatization. The questionnaire contains 92 items of which 68 items indicate symptoms and 24 items are antonyms of some of the symptoms that indicate well-being. The maximum score for each symptom subscale is 17, the well-being subscales 6 and for the total scale scores 23. A higher score indicates more distress than a lower score. The total subscale scores will be unevaluable if less than 19 of the 23 items are recorded. If 19 to 22 of the 23 items are recorded, the total subscale score is the mean of the recorded items multiplied by 23 and then rounded to the first decimal place. The total score will be unevaluable if less than 76 of the 92 items are recorded. If 76 to 91 of the 92 items and no less than 19 of the 23 items of each subscale are recorded, the total score will be the mean of the recorded items multiplied by 92 and then rounded to the first decimal place.

    Time frame: Baseline, Week 6

  11. Mean Change From Baseline in Go/No-Go Task for P-inhibition Failures

    Executive function and working memory were assessed for the Go/No-go Task using computer-based and paper-pencil neuropsychological instruments. These instruments focused on measuring impulse inhibition. The instrument was administered at the following visits: Baseline and Week 6/ET.

    Time frame: Baseline, Week 6

  12. Mean Change From Baseline in Go/No-Go Task for Mean Reaction Time

    Executive function and working memory were assessed for the Go/No-go Task using computer-based and paper-pencil neuropsychological instruments. These instruments focused on measuring impulse inhibition. The instrument was administered at the following visits: Baseline and Week 6/ET.

    Time frame: Baseline, Week 6

  13. Mean Change From Baseline in Delay Discounting Task - Monetary Choice Questionnaire (MCQ) Score

    Delay discounting was a participant-completed task is an index of impulsive behavior. It measured the extent to which the value of a reward decreased as the delay to obtaining that reward increased. The propensity of participants to delay reward was assessed with an MCQ. Discounting rate is estimated using, k= (A/V)1/D, where k is the discounting rate parameter, V is the immediate reward, A is the higher delayed reward and D is the amount of days to the delayed reward. The MCQ consists of 27 choices between immediate and delayed rewards. The participant chooses repeatedly between 2 hypothetical sums of money: a smaller amount now or a larger amount in the future (for example, "would you prefer $27 today or $50 in 21 days?") The answers provide an estimate of the participant's discounting rate; higher discounting rates indicate greater impulsivity. A total score is not computed for all 27 questions.

    Time frame: Baseline, Week 6

  14. Mean Change From Baseline in Delay and Probability Discounting Task (DPDT) Scores

    The experiential discounting task (EDT) was a subject-completed computerized task designed to measure delay discounting, an index of impulsive behavior. It measured the extent to which the value of a reward decreased as the delay to obtaining that reward increased. The participant chose between different amounts of money available at different delays or with different chances (probability to get the money). At the end of the session, one of the choices was selected at random, and the participant received whatever they chose in response of that question (immediate, delayed, or probabilistic amount). Formula for h-value: value = A / (1 + hO) p is probability of reward and O is odds against. The value of h indicates how the value of a reward and the probability of its occurrence decreases. The data are computerized and reflect delay discounting and impulsivity (higher discounting and higher probability discounting shows greater impulsivity). A total score is not computed for this task.

    Time frame: Baseline, Week 6

  15. Mean Change From Baseline to Week 6 in the Number of Impulsive Choices in the Delayed Reward Task (DRT)

    Delay discounting was a participant-completed task considered as an index of impulsive behavior. It measured the extent to which the value of a reward decreased as the delay to obtaining that reward increased. During a training session, a single button with letter A or B appeared on the screen. The participant had to wait until the letter began to flash, and press the button only once. An amount of money was added to a counter and another single button appeared. During the test session, both buttons with letters A and B appeared on the screen. The participant had to choose one of the letters that remained; the other disappeared. The participant had to wait until the letter began to flash and then press the button again. An amount of money was added to the counter, and both letters appeared again. The data are computerized and reflect delay discounting and impulsivity (higher discounting shows greater impulsivity). A total score was not calculated for this task.

    Time frame: Baseline, Week 6

  16. Mean Change From Baseline in Food Delay Discounting Task

    Delay discounting was a participant-completed task considered as an index of impulsive behavior. The participant chooses between a reward they could have today and another that they could get after a specified amount of time. The participant would not receive the rewards, but was asked to make decisions as though he or she were really going to receive them. AUC is defined as area under the concentration-time curve; AUC for food is presented below. The data are computerized and reflect delay discounting and impulsivity (higher discounting shows greater impulsivity). To calculate the AUC, the "X-axis" is "days", "Y-axis" is "Food value", the actual area underneath the curve was calculated by summing the results for each delay and present value pair: x2 -x1\[(y1 + y2)/2\], where x1 and x2 are successive delays and y1 and y2 are the present values associated with those delays. The AUC can range from 1 (no discounting) to 0 (maximum discounting).

    Time frame: Baseline, Week 6

  17. Mean Change From Baseline in Money Delay Discounting Task

    Delay discounting was a participant-completed task considered as an index of impulsive behavior. The participant chose between a reward they could have today and another that they could get after a specified amount of time. The participant would not receive the rewards, but was asked to make decisions as though he or she were really going to receive them. AUC is defined as area under the concentration-time curve; AUC for money is presented below. The data are computerized and reflect delay discounting and impulsivity (higher discounting shows greater impulsivity). To calculate the AUC, the "X-axis" is "days", "Y-axis" is "Money value", the actual area underneath the curve was calculated by summing the results for each delay and present value pair: x2 -x1\[(y1 + y2)/2\], where x1 and x2 are successive delays and y1 and y2 are the present values associated with those delays. The AUC can range from 1 (no discounting) to 0 (maximum discounting).

    Time frame: Baseline, Week 6

  18. Mean Change From Baseline in Barratt Impulsiveness Scale 11-item (BIS-11) Total Score

    The BIS-11 was a participant-rated scale designed to assess impulsive personality traits. The BIS-11 consisted of 30 items scored on a 4-point scale ranging from 1 (rarely/never) to 4 (almost always/always). The scores provided information to assess 6 first-order factors (attention, motor, self-control, cognitive complexity, perseverance, and cognitive instability impulsiveness) and 3 second-order factors (motor impulsiveness, non-planning impulsiveness, and attentional impulsiveness). The total score ranged from 30 to 120, with higher scores indicating impulsive personality traits. The BIS-11 was administered at the following visits: Baseline and Week 6/ET.

    Time frame: Baseline, Week 6

07

Results

Posted Mar 29, 2016

Participant flow

This trial was conducted in 37 participants. 18 trial sites were initiated in the United Sates, and 12 trial sites enrolled participants.

Participant flow — Overall Study
MilestoneBrexpiprazole
Started37
Completed32
Not completed5
Withdrew: Lost to follow-up3
Withdrew: Met withdrawal criteria1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryMean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

The MADRS is utilized as the primary efficacy assessment of a participant's level of depression. The MADRS consists of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS Total Score is the sum of ratings for all 10 items. The possible Total scores are from 0 to 60, with higher values indicating worse outcome.

Time frame:
Baseline, Week 6
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
Units on a scaleBrexpiprazole
Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score-19.6 ± 1.5
Statistical analysis
  • Brexpiprazole · Mixed Models Analysis · p = <0.0001MMRM with model terms: Baseline, visit, and Baseline by visit interaction
SecondaryMean Change in Clinical Global Impression-Severity (CGI-S) Total Score

The severity of illness for each participant was rated using the CGI-S. To perform this assessment, the study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

Time frame:
Baseline, Week 6
Reported as:
Least squares mean · Units on a scale
Mean Change in Clinical Global Impression-Severity (CGI-S) Total Score
Units on a scaleBrexpiprazole
Mean Change in Clinical Global Impression-Severity (CGI-S) Total Score-2.2 ± 0.2
Statistical analysis
  • Brexpiprazole · Mixed Models Analysis · p = <0.0001Mixed model repeated measure (MMRM) with model terms: Baseline, visit, and Baseline by visit interaction
SecondaryMean Clinical Global Impression-Improvement (CGI-I) Score at Week 6.

The improvement of each participants condition was rated for each participant using the CGI-I. The study physician rated the participants total improvement whether or not it was due entirely to drug treatment. To perform this assessment, the study physician answered the following question: "Compared to his/her condition at baseline, how much has the participant changed?" Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. The response at a given week was compared with the participants condition at Baseline prior to the first dose of study medication.

Time frame:
Baseline, Week 6
Reported as:
Mean · Units on a scale
Mean Clinical Global Impression-Improvement (CGI-I) Score at Week 6.
Units on a scaleBrexpiprazole
Mean Clinical Global Impression-Improvement (CGI-I) Score at Week 6.1.9 ± 1.1
SecondaryPercentage of Participants With CGI-I Response Rate

The improvement of each participants condition was rated for each participant using the CGI-I. The study physician rated the participants total improvement whether or not it was due entirely to drug treatment. To perform this assessment, the study physician answered the following question: "Compared to his/her condition at baseline, how much has the participant changed?" Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. The response at a given week was compared with the participants condition at Baseline prior to the first dose of study medication.

Time frame:
Week 1 to Week 6
Reported as:
Number · percentage of participants
Percentage of Participants With CGI-I Response Rate
percentage of participantsBrexpiprazole
Week 18.3
Week 236.1
Week 350.0
Week 466.7
Week 675.0
SecondaryPercentage of Participants With a MADRS Response

MADRS response rate, where response is defined as ≥ 50% reduction in respective total scores from Baseline to Week 6. The MADRS consists of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS Total Score is the sum of ratings for all 10 items. The possible Total scores are from 0 to 60, higher values indicate worse outcome.

Time frame:
Week 6
Reported as:
Number · Percentage of participants
Percentage of Participants With a MADRS Response
Percentage of participantsBrexpiprazole
Percentage of Participants With a MADRS Response69.4
SecondaryPercentage of Participants With a MADRS Remission

MADRS remission rate, where remission is defined as MADRS Total Score ≤ 10 and 50% reduction in MADRS Total Score from Baseline to Week 6. The MADRS consists of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS Total Score is the sum of ratings for all 10 items. The possible Total scores are from 0 to 60, higher values indicate worse outcome.

Time frame:
Week 6
Reported as:
Number · Percentage of participants
Percentage of Participants With a MADRS Remission
Percentage of participantsBrexpiprazole
Percentage of Participants With a MADRS Remission47.2
SecondaryMean Change From Baseline in Hamilton Depression Rating Scale (HAM-D17) Total Score

The HAM-D17 was utilized as an assessment of a participants level of depression and was administered utilizing the Structured Interview Guide for the Hamilton Depression Rating Scale (SIGH-D). Detailed instructions for administration of this structured interview were provided in the SIGH-D. The HAM-D17 was administered at the following visits: screening, Baseline, and Week 6/ Early termination (ET). HAM-D17 is a 17-item questionnaire with a total score of 0 to 52 with higher scores indicating more depressive symptoms.

Time frame:
Baseline, Week 6
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Hamilton Depression Rating Scale (HAM-D17) Total Score
Units on a scaleBrexpiprazole
Mean Change From Baseline in Hamilton Depression Rating Scale (HAM-D17) Total Score-15.85 ± 7.37
SecondaryMean Change From Baseline in Hamilton Anxiety Rating Scale (HAM-A) Total Score

The HAM-A was utilized for the evaluation of anxiety symptoms and was administered using the Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A). Detailed instructions for administration of this structured interview were provided in the SIGH-A. The HAM-A was administered at the following visits: screening, Baseline, Weeks 1, 2, 3, 4, and 6/ET. HAM-A is a 14-item scale with each item is scored on a scale from 0 (not present) to 4 (very severe) with a total score of 0 to 56, with higher scores indicating severe anxiety symptoms.

Time frame:
Baseline, Week 6
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline in Hamilton Anxiety Rating Scale (HAM-A) Total Score
Units on a scaleBrexpiprazole
Mean Change From Baseline in Hamilton Anxiety Rating Scale (HAM-A) Total Score-17.80 ± 1.23
Statistical analysis
  • Brexpiprazole · Mixed Models Analysis · p = <0.0001Mixed model repeated measure (MMRM) with model terms: Baseline, visit, and Baseline by visit interaction
SecondaryMean Change From Baseline in Sheehan Disability Scale (SDS) Mean Score

The SDS was a self-rated instrument used to measure the effect of the participant's symptoms on work/school, social life, and family/home responsibilities. The SDS was a visual analogue scale that used spatio-visual, numeric, and verbal descriptive anchors simultaneously to assess disability across the 3 domains. The number most representative of how much each area was disrupted by symptoms was marked along the line from 0 = not at all to 10 = extremely. Scores of 5 and above were associated with significant functional impairment. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired).

Time frame:
Baseline, Week 6
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Sheehan Disability Scale (SDS) Mean Score
Units on a scaleBrexpiprazole
Mean Change From Baseline in Sheehan Disability Scale (SDS) Mean Score-3.62 ± 2.60
SecondaryMean Change From Baseline in Massachusetts General Hospital-Cognitive and Physical Functioning Questionnaire (MGH-CPFQ) Total Score

The MGH-CPFQ was a participant-rated scale designed to assess cognitive and executive dysfunction including symptoms of fatigue in mood and anxiety disorders. The MGH-CPFQ consisted of 7 items, each rated on a scale from 1 (greater than normal functioning) to 6 (poorer than normal functioning). The total score of the 7 items ranged from 7 to 42, with higher scores indicative of a worse outcome. The MGH-CPFQ was administered at the following visits: Baseline and Week 6/ET.

Time frame:
Baseline, Week 6
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Massachusetts General Hospital-Cognitive and Physical Functioning Questionnaire (MGH-CPFQ) Total Score
Units on a scaleBrexpiprazole
Mean Change From Baseline in Massachusetts General Hospital-Cognitive and Physical Functioning Questionnaire (MGH-CPFQ) Total Score-9.85 ± 8.79
SecondaryMean Change From Baseline in Kellner Symptom Questionnaire (KSQ)

KSQ is a subject-rated scale designed to assess distress using symptoms of depression, anxiety, anger-hostility and somatization. The questionnaire contains 92 items of which 68 items indicate symptoms and 24 items are antonyms of some of the symptoms that indicate well-being. The maximum score for each symptom subscale is 17, the well-being subscales 6 and for the total scale scores 23. A higher score indicates more distress than a lower score. The total subscale scores will be unevaluable if less than 19 of the 23 items are recorded. If 19 to 22 of the 23 items are recorded, the total subscale score is the mean of the recorded items multiplied by 23 and then rounded to the first decimal place. The total score will be unevaluable if less than 76 of the 92 items are recorded. If 76 to 91 of the 92 items and no less than 19 of the 23 items of each subscale are recorded, the total score will be the mean of the recorded items multiplied by 92 and then rounded to the first decimal place.

Time frame:
Baseline, Week 6
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Kellner Symptom Questionnaire (KSQ)
Units on a scaleBrexpiprazole
Mean Change From Baseline in Kellner Symptom Questionnaire (KSQ)-29.43 ± 20.88
SecondaryMean Change From Baseline in Go/No-Go Task for P-inhibition Failures

Executive function and working memory were assessed for the Go/No-go Task using computer-based and paper-pencil neuropsychological instruments. These instruments focused on measuring impulse inhibition. The instrument was administered at the following visits: Baseline and Week 6/ET.

Time frame:
Baseline, Week 6
Reported as:
Mean · failures
Mean Change From Baseline in Go/No-Go Task for P-inhibition Failures
failuresBrexpiprazole
P-inhibition failures (Go cues)-0.0193 ± 0.2324
P-inhibition failures (No-Go cues)-0.0103 ± 0.2337
SecondaryMean Change From Baseline in Go/No-Go Task for Mean Reaction Time

Executive function and working memory were assessed for the Go/No-go Task using computer-based and paper-pencil neuropsychological instruments. These instruments focused on measuring impulse inhibition. The instrument was administered at the following visits: Baseline and Week 6/ET.

Time frame:
Baseline, Week 6
Reported as:
Mean · milliseconds
Mean Change From Baseline in Go/No-Go Task for Mean Reaction Time
millisecondsBrexpiprazole
Mean reaction time (Go cues)-0.26 ± 52.49
Mean reaction time (No-Go cues)-4.26 ± 51.69
SecondaryMean Change From Baseline in Delay Discounting Task - Monetary Choice Questionnaire (MCQ) Score

Delay discounting was a participant-completed task is an index of impulsive behavior. It measured the extent to which the value of a reward decreased as the delay to obtaining that reward increased. The propensity of participants to delay reward was assessed with an MCQ. Discounting rate is estimated using, k= (A/V)1/D, where k is the discounting rate parameter, V is the immediate reward, A is the higher delayed reward and D is the amount of days to the delayed reward. The MCQ consists of 27 choices between immediate and delayed rewards. The participant chooses repeatedly between 2 hypothetical sums of money: a smaller amount now or a larger amount in the future (for example, "would you prefer $27 today or $50 in 21 days?") The answers provide an estimate of the participant's discounting rate; higher discounting rates indicate greater impulsivity. A total score is not computed for all 27 questions.

Time frame:
Baseline, Week 6
Reported as:
Mean · unitless
Mean Change From Baseline in Delay Discounting Task - Monetary Choice Questionnaire (MCQ) Score
unitlessBrexpiprazole
Mean Change From Baseline in Delay Discounting Task - Monetary Choice Questionnaire (MCQ) Score-0.008442 ± 0.060200
SecondaryMean Change From Baseline in Delay and Probability Discounting Task (DPDT) Scores

The experiential discounting task (EDT) was a subject-completed computerized task designed to measure delay discounting, an index of impulsive behavior. It measured the extent to which the value of a reward decreased as the delay to obtaining that reward increased. The participant chose between different amounts of money available at different delays or with different chances (probability to get the money). At the end of the session, one of the choices was selected at random, and the participant received whatever they chose in response of that question (immediate, delayed, or probabilistic amount). Formula for h-value: value = A / (1 + hO) p is probability of reward and O is odds against. The value of h indicates how the value of a reward and the probability of its occurrence decreases. The data are computerized and reflect delay discounting and impulsivity (higher discounting and higher probability discounting shows greater impulsivity). A total score is not computed for this task.

Time frame:
Baseline, Week 6
Reported as:
Mean · unitless
Mean Change From Baseline in Delay and Probability Discounting Task (DPDT) Scores
unitlessBrexpiprazole
Delay discounting task k value-3.586888 ± 15.156644
Probability discouting task h value3.505900 ± 28.036537
SecondaryMean Change From Baseline to Week 6 in the Number of Impulsive Choices in the Delayed Reward Task (DRT)

Delay discounting was a participant-completed task considered as an index of impulsive behavior. It measured the extent to which the value of a reward decreased as the delay to obtaining that reward increased. During a training session, a single button with letter A or B appeared on the screen. The participant had to wait until the letter began to flash, and press the button only once. An amount of money was added to a counter and another single button appeared. During the test session, both buttons with letters A and B appeared on the screen. The participant had to choose one of the letters that remained; the other disappeared. The participant had to wait until the letter began to flash and then press the button again. An amount of money was added to the counter, and both letters appeared again. The data are computerized and reflect delay discounting and impulsivity (higher discounting shows greater impulsivity). A total score was not calculated for this task.

Time frame:
Baseline, Week 6
Reported as:
Mean · Number of Impulsive Choices
Mean Change From Baseline to Week 6 in the Number of Impulsive Choices in the Delayed Reward Task (DRT)
Number of Impulsive ChoicesBrexpiprazole
Mean Change From Baseline to Week 6 in the Number of Impulsive Choices in the Delayed Reward Task (DRT)4.6 ± 18.1
SecondaryMean Change From Baseline in Food Delay Discounting Task

Delay discounting was a participant-completed task considered as an index of impulsive behavior. The participant chooses between a reward they could have today and another that they could get after a specified amount of time. The participant would not receive the rewards, but was asked to make decisions as though he or she were really going to receive them. AUC is defined as area under the concentration-time curve; AUC for food is presented below. The data are computerized and reflect delay discounting and impulsivity (higher discounting shows greater impulsivity). To calculate the AUC, the "X-axis" is "days", "Y-axis" is "Food value", the actual area underneath the curve was calculated by summing the results for each delay and present value pair: x2 -x1\[(y1 + y2)/2\], where x1 and x2 are successive delays and y1 and y2 are the present values associated with those delays. The AUC can range from 1 (no discounting) to 0 (maximum discounting).

Time frame:
Baseline, Week 6
Reported as:
Mean · unitless
Mean Change From Baseline in Food Delay Discounting Task
unitlessBrexpiprazole
Mean Change From Baseline in Food Delay Discounting Task0.0371 ± 0.1819
SecondaryMean Change From Baseline in Money Delay Discounting Task

Delay discounting was a participant-completed task considered as an index of impulsive behavior. The participant chose between a reward they could have today and another that they could get after a specified amount of time. The participant would not receive the rewards, but was asked to make decisions as though he or she were really going to receive them. AUC is defined as area under the concentration-time curve; AUC for money is presented below. The data are computerized and reflect delay discounting and impulsivity (higher discounting shows greater impulsivity). To calculate the AUC, the "X-axis" is "days", "Y-axis" is "Money value", the actual area underneath the curve was calculated by summing the results for each delay and present value pair: x2 -x1\[(y1 + y2)/2\], where x1 and x2 are successive delays and y1 and y2 are the present values associated with those delays. The AUC can range from 1 (no discounting) to 0 (maximum discounting).

Time frame:
Baseline, Week 6
Reported as:
Mean · unitless
Mean Change From Baseline in Money Delay Discounting Task
unitlessBrexpiprazole
Mean Change From Baseline in Money Delay Discounting Task0.0707 ± 0.2284
SecondaryMean Change From Baseline in Barratt Impulsiveness Scale 11-item (BIS-11) Total Score

The BIS-11 was a participant-rated scale designed to assess impulsive personality traits. The BIS-11 consisted of 30 items scored on a 4-point scale ranging from 1 (rarely/never) to 4 (almost always/always). The scores provided information to assess 6 first-order factors (attention, motor, self-control, cognitive complexity, perseverance, and cognitive instability impulsiveness) and 3 second-order factors (motor impulsiveness, non-planning impulsiveness, and attentional impulsiveness). The total score ranged from 30 to 120, with higher scores indicating impulsive personality traits. The BIS-11 was administered at the following visits: Baseline and Week 6/ET.

Time frame:
Baseline, Week 6
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Barratt Impulsiveness Scale 11-item (BIS-11) Total Score
Units on a scaleBrexpiprazole
Mean Change From Baseline in Barratt Impulsiveness Scale 11-item (BIS-11) Total Score-7.67 ± 10.14

Adverse events

Collected over Adverse events were reported from the signing of the informed consent until the follow-up visit of 30 (+2 days).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brexpiprazole—1/37 (2.7%)28/37 (75.7%)
Most frequent serious events
Most frequent serious events
EventBrexpiprazole
PneumoniaInfections and infestations1/37
Most frequent other events
Showing 10 of 15
Most frequent other events
EventBrexpiprazole
Increased appetiteMetabolism and nutrition disorders5/37
DiarrhoeaGastrointestinal disorders4/37
Dry mouthGastrointestinal disorders4/37
DizzinessNervous system disorders4/37
Musculoskeletal stiffnessMusculoskeletal and connective tissue disorders3/37
FatigueGeneral disorders2/37
InfluenzaInfections and infestations2/37
ArthralgiaMusculoskeletal and connective tissue disorders2/37
Neck painMusculoskeletal and connective tissue disorders2/37
AkathisiaNervous system disorders2/37

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Brexpiprazole
Mean45.7 ± 15.2
Sex: Female, Male
Sex: Female, Male(Participants)Brexpiprazole
Female26
Male11
08

Study locations

21 sites
  • Tuscon, Arizona 85712, United States
  • Garden Grove, California 92845, United States
  • Oceanside, California 92056, United States
  • Temecula, California 92591, United States
  • Gainesville, Florida 32607, United States
  • Jacksonville, Florida 32256, United States
  • Miami, Florida 33145, United States
  • Atlanta, Georgia 30308, United States
  • Lafayette, Indiana 47905, United States
  • Baltimore, Maryland 21208, United States
  • Boston, Massachusetts 02131, United States
  • Haverhill, Massachusetts 01830, United States
  • Rochester Hills, Michigan 48307, United States
  • New York, New York 10168, United States
  • Staten Island, New York 10305, United States
  • Salem, Oregon 97301, United States
  • Allentown, Pennsylvania 18104, United States
  • Arlington, Texas 76012, United States
  • Austin, Texas 78731, United States
  • Woodstock, Vermont 05091, United States
  • Richmond, Virginia 23230, United States
09

References and documents

Publications

  • Weiss C, Meehan SR, Brown TM, Gupta C, Morup MF, Thase ME, McIntyre RS, Ismail Z. Effects of adjunctive brexpiprazole on calmness and life engagement in major depressive disorder: post hoc analysis of patient-reported outcomes from clinical trial exit interviews. J Patient Rep Outcomes. 2021 Dec 11;5(1):128. doi: 10.1186/s41687-021-00380-4. PubMed 34894307 ↗
  • Davis LL, Ota A, Perry P, Tsuneyoshi K, Weiller E, Baker RA. Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study. Brain Behav. 2016 Jul 24;6(10):e00520. doi: 10.1002/brb3.520. eCollection 2016 Oct. PubMed 27781135 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2013, a primary completion of May 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2016, 1 year 10 months after primary completion. A results delay was requested in Apr 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2013
First posted
Dec 17, 2013
Start
Nov 2013
Primary completionActual
May 2014
CompletionActual
Jun 2014
Results delay requested
Apr 30, 2015
Results first posted
Mar 29, 2016
Last update
Mar 29, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02013531
Responsible party
Sponsor
First posted
Dec 17, 2013
Start date
Nov 2013
Primary completion
May 2014
Completion
Jun 2014
Results posted
Mar 29, 2016
Last update
Mar 29, 2016

Study contacts

Junichi Hashimoto, PhD
study director · Otsuka Pharmaceutical Co., Ltd Japan (OPCJ)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion